News

August 18th, 2017
Immunovia invites to a conference call on August 23, 2017

Immunovia invites to a conference call in connection with reporting the half-year results 2017. The conference call will take place at 16:00 on August 23 and the result is expected to be published at 8:30 AM the same day. The conference call, scheduled to last for a maximum of one hour, will be held in […]

July 17th, 2017
Leading pancreatic cancer expert on early symptoms Professor Stephen Pereira at University College London joins Immunovia’s Scientific Advisory Board

LUND, Sweden ― Immunovia announced today that Professor Stephen Pereira, one of the globally leading experts in the diagnosis of early symptoms of pancreatic cancer and a multidisciplinary diagnostic center champion has been appointed to the company’s Scientific Advisory Board. Currently, Pereira is Professor of Hepatology & Gastroenterology at UCL, University College London, and an […]

June 30th, 2017
Immunovia together with Oregon Health and Science University awarded one of the prestigious Pancreatic Cancer Action Network 2017 Research Grants

LUND, Sweden ― On the 28th of June, it was announced that Pancreatic Cancer Action Network (PanCAN), the largest patient advocacy group in USA, in partnership with generous donors, awarded Prof. Brett Sheppard and Prof. Rosalie Sears from Oregon Health and Science University one of the Research grants for 2017 of a value of $ […]

June 28th, 2017
Immunovia establishes headquarter for US operations in Boston including CLIA reference laboratory

LUND, Sweden ― Immunovia today announces that Boston, Massachusetts USA, has been chosen as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB, and that the facility agreements have been finalized.  This new Immunovia site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as […]

June 21st, 2017
Immunovia’s IMMray™ presents biomarkers that differentiates Rheumatoid Arthritis from other autoimmune diseases with 89% accuracy

LUND, Sweden – Immunovia today announced that they have completed the analysis of the three other autoimmune diseases included in the previously reported large, retrospective autoimmune disease study, performed in collaboration with Department of Immuntechnology, Lund University. The study included 315 blood samples and covered main autoimmune indications such as, Systemic Lupus Erythematosus Rheumatoid Arthritis […]

June 16th, 2017
New Immunovia logotype

Immunovia reveals today the new logotype, one that can continue to grow and adapt with the development of the IMMray™ technology and its clinical applications in cancers and autoimmune diseases. This brand identity change is important for Immunovia for three reasons: -The company name is now easy to read and understand -New IMMray™ based tests […]

June 16th, 2017
Immunovia AB announces timetable for listing on Nasdaq Stockholm’s main market

LUND, Sweden – The Board of Directors of Immunovia AB today announces timetable for the application for listing of the company’s shares on Nasdaq Stockholm’s main market. Immunova’s shares are currently traded on Nasdaq First North under the ticker IMMNOV. The company’s preparations of internal processes to meet the requirements on the main market are […]

June 13th, 2017
Immunovia´s biomarker signature for the diagnosis of pancreatic cancer now patented in Japan

LUND, Sweden ― Immunovia is delighted to announce the grant by the Japanese Patent Office of a patent for its biomarker signature for the diagnosis of pancreatic cancer.  Japanese Patent No. JP 6115801 is the first patent awarded to Immunovia in Japan covering its proprietary IMMray™ PanCan-d test. Immunovia CEO, Mats Grahn, commented “The grant […]

April 25th, 2017
Immunovia Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299, har hållits den 25 april 2017 i Gamla Gästmatsalen på Medicon Village, Scheelevägen 2, Lund. Nedan följer en sammanfattning av de beslut som fattades. Disposition av bolagets vinst och förlust Stämman beslutade att till förfogande stående vinstmedel om 251 497 840 kr överförs i ny räkning. Arvode till styrelse och […]

April 20th, 2017
Immunovia Interim report, January-March 2017

“During the quarter we reported from a significant study that showed our ability to differentiate between SLE and other common autoimmune diseases. The very good results of the study, which indicated that SLE can be differentiated with 96% accuracy against a mix of healthy, rheumatoid arthritis, Sjögren’s disease and vasculitis patient samples, give us a […]

April 19th, 2017
Immunovia inbjuder till telefonkonferens den 20 april 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av första kvartalet 2017. Telefonkonferensen äger rum kl. 16:00 den 20 april och resultatet beräknas publiceras kl. 8:30 samma dag. Immunovia inbjuder till telefonkonferens i samband med rapportering av första kvartalet 2017. Telefonkonferensen som beräknas pågå i maximalt en timme kommer att hållas på svenska. Efter en […]

March 24th, 2017
IMMUNOVIA AB KALLAR TILL ÅRSSTÄMMA OCH PUBLICERAR ÅRSREDOVISNING FÖR RÄKENSKAPSÅRET 2016

Styrelsen i Immunovia AB (publ), org nr 556730-4299, kallar härmed till årsstämma. Datum:                                           25 april 2017 Tid:                                                 15.00 Plats:                                              Gamla Gästmatsalen, Inspira, Medicon Village, Scheelevägen 2, Lund  Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman skall vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 19 april 2017 och senast denna […]

March 7th, 2017
Final data from major Swedish study confirms that IMMray™ biomarker microarray differentiates systemic lupus erythematosus (SLE) from other autoimmune diseases with 96% accuracy

LUND, Sweden: Immunovia today announced that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s IDEA Centre has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray™ blood-based biomarker signatures in differentiating SLE from three other main autoimmune […]

February 22nd, 2017
Immunovia tillkännager genomförd blocktransaktion i bolagets aktier

-Befintliga och nya institutionella och professionella investerare förvärvar aktier genom en blocktransaktion. -Transaktionen genomfördes till priset av 95 kronor per aktie. -Säljande parter har förbundit sig till nya lock up-restriktioner fram till och med utgången av 2017. Immunovia tillkännagav idag en förändring i bolagets ägarstruktur. Totalt 400 000 aktier, motsvarande 2,4 procent av bolagets aktiekapital, såldes […]

February 15th, 2017
Immunovia Financial Statement 2016

2016 in Summary -Prospective validation study of the hereditary risk group for pancreatic cancer started as planned at the end of 2016. -IMMray™ PanCan–d validated in an American patient cohort. 96% accuracy confirmed for early detection of pancreatic cancer. -Collaboration with the US National Center Institute to focus on early onset diabetes patients aged over […]

February 14th, 2017
Immunovia inbjuder till telefonkonferens den 15 februari 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av helårsresultatet för 2016. Telefonkonferensen äger rum kl. 16.00 den 15 februari och resultatet beräknas publiceras kl. 08.00 samma dag. Immunovia inbjuder till telefonkonferens i samband med rapportering av helårsresultatet för 2016. Telefonkonferensen som beräknas pågå i maximalt en timme kommer att hållas på svenska. Efter en […]

February 13th, 2017
Immunovia presenterar vid Vator Securities Unicorn Summit

Vator Securities Unicorn Summit är en kapitalmarknadsdag med några av de mest intressanta svenska Life Science-bolagen. Eventet anordnas den 7 mars 2017 på IVA i Stockholm, med start klockan 11.30. LUND, Sverige – Immunovia AB är ett av sju utvalda bolag som ska presentera under eftermiddagen. För presentationen, som börjar klockan 14.30 står Mats Grahn, […]

February 3rd, 2017
Professor Borrebaeck in Nature Reviews Cancer online magazine

Nature Reviews Cancer magazine published today online, ahead of print an article focused on Precision Diagnostics. This Opinion article, written by Professor Carl Borrebaeck, describes the trends and progress being made in identifying protein biomarker signatures of clinical utility in cancer using, in particular, blood-based proteomics. Click to read article. Pdf for download Title: Precision […]

January 16th, 2017
University of Michigan Pancreatic Cancer Center new partner in Immunovia’s global PANFAM-1 prospective validation study

LUND, Sweden, and Ann Arbor, USA ― Immunovia AB is pleased to announce that the University of Michigan Pancreatic Cancer Center has become the most recent member of the global network of prominent sites participating in the PANFAM-I prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals. Designed to validate […]

January 13th, 2017
Immunovia bjuder in till telefonkonferens tisdag 17/1 kl 16:00

Med anledning av gårdagens offentliggörande av studieresultaten där Immunovia kan påvisa att IMMray™ biomarkörsignatur kan särskilja Systemic Lupus Erythematosus (SLE) med 90 procents träffsäkerhet från andra autoimmuna sjukdomar, inbjuder Immunovia till telefonkonferens på tisdag 17 januari, kl 16:00.  Datum: 17 januari 2017 Tid: 16:00 (CET) Telefonnummer: CH: +41 225675548 DE: +49 69222229046 UK: +44 2030089803 SE: +46 […]

January 12th, 2017
Immunovia announces the first data exceeding 90% accuracy in distinguishing systemic lupus erythematosus (SLE) from other autoimmune diseases in a new study

LUND, Sweden ― Immunovia today announced that the principal aim of a large retrospective study, performed in collaboration with Lund University’s IDEA Centre, has been achieved. The data confirms that IMMray™ biomarker signatures can distinguish Systemic Lupus Erythematosus (SLE) from three other main autoimmune diseases, rheumatoid arthritis, Sjögren’s disease and vasculitis with an average accuracy […]

December 22nd, 2016
Immunovia Shareholder Newsletter Q4 2016

Dear Immunovia Shareholders, With the end of the year approaching and many of you looking forward to a well-deserved Christmas and New Year celebration, we at Immunovia would also like you to join us in celebrating an unprecedented year which we are sure you would agree has more than surpassed expectations. In this newsletter, we […]

December 20th, 2016
Immunovia bjuder in till telefonkonferens idag 20/12 kl 16:00

Med anledning av den för Immunovia viktiga starten av den prospektiva studien som annonserades tidigare idag och betydelsen av detta för IMMray™ PanCan–d att i förlängningen inkluderas i nationella guidelines inbjuder Immunovia till telefonkonferens idag tisdagen den 20 december, kl 16.00. Datum: 20 december 2016 Tid: 16:00 (CET) Telefonnummer: CH: +41225675541 DE: +4969222229046 UK: +442030089808 SE: +46856642694 Uppge ditt […]

December 20th, 2016
Immunovia announces the start of PANFAM-1, the largest ever prospective multi-center clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer LUND, Sweden, and MADRID, Spain ― Immunovia AB today announced the start of PANFAM-1, a multicenter prospective validation study for the early diagnosis in familiar pancreatic cancer (FPC) high risk individuals. The first site now collecting blood samples is the […]

December 12th, 2016
Immunovia bjuder in till telefonkonferens torsdag 15/12 kl 16:00

Datum: 15 december 2016 Tid: 16:00 (CET) Telefonnummer: SE: +46856642662 CH: +41225675548 DE: +4969222229046 UK: +44 2030089804 Uppge ditt förnamn och efternamn samt företag om du vill lyssna på telefonkonferensen. För att ställa en fråga under Q&A tryck 01. För frågor samt för tidsbokning av intervjuer: ir@immunovia.com  På Immunovias hemsida under Investerare/Nyhetsarkiv/Ljud- och videoinspelningar (http://immunovia.com/sv/investerare/nyhetsarkiv/ljud-och-video-inspelningar/) kommer […]

December 9th, 2016
Summary from the extraordinary general meeting of Immunovia

Extraordinary General Meeting of Immunovia AB (publ), 556730-4299, has been held in the confernce room ”Gamla Gästmatsalen”, House 302, Medicon Village, Scheelevägen 2, 223 63 Lund, December 9, 2016. Below is a summary of the resolutions of the extraordinary general meeting. Election of Board of Directors It was noted that the board member Patrik Dahlén […]

December 9th, 2016
Immunovia announces collaboration with NCI, regarding early detection of pancreatic cancer in the new onset diabetes risk group

Immunovia and NCI (National Cancer Institute), has in a memorandum of understanding agreed to collaborate towards a common goal of cancer biomarker development and validation, in particular regarding early detection of pancreatic cancer in the risk group of new onset diabetes over 50 years. LUND, Sweden ― Immunovia AB is delighted to announce a collaboration […]

December 9th, 2016
Immunovia announces collaboration with the renowned Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid to validate the company´s early detection blood based test for pancreatic cancer in a prospective clinical study

LUND, Sweden, and MADRID, Spain ― Immunovia AB is delighted to announce the addition of the leading Spanish research centre Ramon y Cajal Institute for Health Research (IRYCIS) to a global network of leading sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals. Designed to validate […]

November 18th, 2016
Immunovia awarded 2016 Stars of Innovation Prize

Leading-edge healthcare diagnostics company making major progress in Europe (LUND, Sweden) ― Leading Swedish diagnostics company Immunovia today announced that it has won the Stars of Innovation category in the European Small- and Mid-Cap Awards 2016. The nomination is recognition of the company’s stellar performance since listing in Stockholm in December last year. During this […]

November 16th, 2016
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (publ)

Styrelsen i Immunovia AB (publ), org nr 556730-4299, kallar härmed till extra bolagsstämma. Datum:    2016-12-09 Tid:           11.00 Plats:        Gamla Gästmatsalen, Hus 302, Medicon Village, Scheelevägen 2, 223 63 Lund Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman skall vara införd i den av Euroclear Sweden AB förda aktieboken lördagen den 3 december 2016 (vilket dock […]

November 4th, 2016
Welcome to World Pancreatic Cancer Day, Lund Sweden, November 17 2016

Every day, more than 900 people around the world die from pancreatic cancer. Only 6 percent of the patients diagnosed with pancreatic cancer survive 5 years. According to a recent global survey, more than 60 percent of people know “almost nothing” about pancreatic cancer. To create awareness about pancreatic cancer, patient support organizations, industry, healthcare providers and politicians join […]

November 4th, 2016
On a mission to advance pancreatic cancer awareness

Pancreatic cancers are one of the most deadly cancers. The cancers are often diagnosed late, making them one of the most hard-to-treat cancers. To create awareness on the aggressive diseases and stir a political discussion for better care, the Medicon Village based company Immunovia is taking the lead on organizing an event at Medicon Village. […]

October 19th, 2016
Immunovia announces successful completion of preferential rights issue of SEK 28.7 million, adding to previously completed SEK 189.9 million directed issue

(LUND, Sweden) ― Immunovia AB, the Swedish molecular diagnostics company, announces today that it has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee. 285,072 new […]

October 19th, 2016
WORLD PANCREATIC CANCER DAY, LUND SWEDEN – It’s About Time

SAVE THE DATE: November 17, 2016 Every day, more than 900 people around the world die from pancreatic cancer. Only 6 percent of the patients diagnosed with pancreatic cancer survive 5 years. According to a recent global survey, more than 60 percent of people know “almost nothing” about pancreatic cancer. On November 17, 2016, Immunovia […]

October 13th, 2016
Immunovia chosen as one of the three most innovative small to mid-companies in Europe 2016

Stars of Innovation nomination recognizes stellar performance since IPO (LUND, Sweden) ― Leading Swedish diagnostics company Immunovia today announced that it has been shortlisted for the Stars of Innovation category in the European Small- and Mid-Cap Awards 2016. The nomination is recognition of the company’s stellar performance since listing in Stockholm in December last year. […]

October 7th, 2016
Immunovia: Insiders transfer subscription rights free of charge

LUND, Sweden ― Within the framework of the ongoing rights issue at Immunovia AB (publ) (“the company”) Carl Borrebaeck and Christer Wingren, Chairman of the Board and Chief Technical Officer respectively at the company, have, on request from professional investors and in consultation with the company’s financial advisor Vator Securities, transferred all subscription rights received […]

September 30th, 2016
Insights on the collaboration between Immunovia and the Knight Cancer Institute, Oregon Portland US, in the latest Vatorpod

In this episode of the Vatorpod, Immunovia’s CEO Mats Grahn and Dr. Joseph Carroll, Senior Director of Business Development & Commercialization at Knight Cancer Institute in Oregon, Portland, US are being interviewed about the crucial importance of early diagnosis in cancer. Click here to listen to the Vatorpod About Dr. Joseph Carroll In his current role managing business development […]

September 26th, 2016
Immunovia publishes prospectus regarding preferential rights issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in connection […]

September 15th, 2016
The board of directors of Immunovia resolves on a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Summary -The board of directors (the “Board”) of Immunovia AB (publ) […]

September 14th, 2016
Immunovia intends to launch a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Summary -Immunovia AB (publ) (”Immunovia” or the ”Company”) intends to launch […]

September 5th, 2016
Immunovia holding detailed talks about participation in a large consortium that will address the largest risk group for pancreatic cancer, new diabetic sufferers aged over 50

The best chance to influence the survival of non-hereditary pancreatic cancer patients is to focus on early detection of cases in people aged over 50 who receive their first diagnosis of diabetes. There is now clear unanimity on this, and both public authorities and health institutes focused on the link between diabetes and pancreatic cancer […]

August 24th, 2016
Immunovia Half-year report 2016

“Immunovia reached several important milestones in the first six months of 2016. Good results were obtained in the American pancreas study that was carried out in collabo­ration with Knight Cancer Institute. Presentations made at the key global conferences concerning pancreatic cancer were very well received. A specially strong Scientific Advisory Board has been recruited, and […]

August 17th, 2016
Immunovia invitation to a teleconference on 24 August 2016

Immunovia invites you to a teleconference in connection with the publishing of the first half-year report for 2016. The conference call will take place at 10 a.m. on 24 August and the results will be published at around 8.30 a.m. the same day. Immunovia invites you to a teleconference in connection with the publishing of […]

August 16th, 2016
Immunovia announces intention to apply for listing on Nasdaq Stockholm’s Main Market


The Board of Immunovia AB (publ) (“Immunovia” or the “Company”) today announces its intention to apply during the first half of 2017 for a listing of its shares on Nasdaq Stockholm’s Main Market. Immunovia’s shares are currently admitted for trading on the Nasdaq First North under the IMMNOV ticker. “Our shareholder base has gradually become […]

July 15th, 2016
Prof. Diane Simeone from University of Michigan Medical Center becomes latest appointment to Immunovia Scientific Advisory Board

Extensive expertise in clinical tumor management and tumor biomarkers, will help accelerate pancreatic cancer diagnostic program LUND, Sweden ― Immunovia announced today that Prof. Diane Simeone, Greenfield Endowed Professor of Surgery and Physiology at the University of Michigan Medical Center and the Director of the Pancreatic Cancer Center and a leading authority on the management […]

July 5th, 2016
World leading cancer diagnostics expert, Professor Aldo Scarpa appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Aldo Scarpa has been appointed to the company’s Scientific Advisory Board. Professor Scarpa is the Director of the ARC-Net Research Centre for Applied Research on Cancer and Chair of […]

June 23rd, 2016
Leading US gastrointestinal cancer expert, Professor Margaret Tempero appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― As Immunovia maintains progress towards delivering the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Margaret Tempero has been appointed to the company’s Scientific Advisory Board. Currently, Professor Tempero is Director of the UCSF Pancreas Center and leader of the Pancreas Cancer Program at the […]

June 15th, 2016
IMMray™ PanCan-d poster presentation at the International Symposium on Pancreatic Cancer in Glasgow, UK, June 9-12 2016

The International Symposium on Pancreatic Cancer, “Pancreas 2016”, that took place in Glasgow UK last week, brought together 350 medical oncologists, surgeons, radiographers, gastroenterologists, molecular pathologists, pathologists and clinical and basic scientists from all over the globe, to explore current knowledge in the diagnosis and treatment of pancreatic cancer. Prof. Carl Borrebaeck, Lund University, Sweden, […]

May 31st, 2016
Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299 har hållits lokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund den 30 maj 2016. Nedan följer en sammanfattning av de beslut som fattades. Disposition av bolagets vinst och förlust Stämman beslutade att till förfogande stående vinstmedel om 83 086 115 kr överförs i ny räkning. Arvode till […]

May 30th, 2016
Double pancreatic cancer survival by 2020

World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer Research (AACR) Pancreatic Cancer Special Conference brought together patient advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando, Florida to discuss pancreatic cancer, a disease with the lowest survival rates of any major cancer. Prof Borrebaeck presented in his AACR talk how serum biomarker […]

May 30th, 2016
96 % of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort

Second study validates Immunovia´s IMMray™ PanCan-d test for early detection of pancreatic cancer (LUND, Sweden) ― Immunovia announced today that they have completed a second retrospective clinical validation study showing 96% accuracy for early detection of 90 early stage I & II North American pancreatic cancer patients, which perfectly matches the previously reported Scandinavian study […]

May 18th, 2016
Inbjudan till Immunovia Informationsmöte i Stockholm den 1 juni kl 17.30 med VD Mats Grahn och Styrelseordförande Carl Borrebaeck

Aktieägare som inte har möjlighet att deltaga på Immunovias bolagsstämma den 30 maj i Lund samt övriga intresserade hälsas välkomna till ett informationsmöte där VD Mats Grahn och Styrelseordförande Carl Borrebaeck informerar om bolagets utveckling under 2015 och därefter. Informationsmötet hålls på Spårvagnshallarna, Birger Jarlsgatan 57A, Stockholm med start kl 17.30 den 1 Juni. Anmälan till […]

May 9th, 2016
Immunovia joins more than 40 global pancreatic cancer organizations at inagural meeting

World Pancreatic Cancer Coalition Aims to Raise Unprecedented Awareness for a Disease with the Lowest Survival Rate of Any Major Cancer LUND, Sweden – (May 9, 2016) The first-ever World Pancreatic Cancer Coalition (WPCC) will gather for its inaugural meeting in Orlando, Fla., on May 11, 2016, bringing together more than 60 individuals representing 40 […]

April 26th, 2016
Immunovia kallar till årsstämma 2016

Styrelsen i Immunovia AB (publ) har kallat till årsstämma den 30 maj 2016. Stämman kommer att hållas kl 16.00 i samlingslokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund. Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman skall vara införd i den av Euroclear Sweden AB förda aktieboken tisdagen den […]

April 8th, 2016
Immunovia appoints Dr. Marco Del Chiaro from Karolinska Institute to Scientific Advisory Board

Dr. Del Chiaro brings deep experience in surgery of pancreatic diseases and identification of high risk individuals for pancreatic cancer LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Dr. Marco Del Chiaro, a world recognized expert surgeon in […]

April 1st, 2016
NOTE about Immunovia and IMMray™ technology information on newswires and social media

Lund, Sweden – During the last months, Immunovia’s news and press releases have caught the attention of social media and journalists around the world. Due to the nature of the Internet, several articles have been published and will continue to be published not only by Immunovia chosen news channels but also by communities of independent […]

March 9th, 2016
Immunovia partners with leading healthcare consulting services firm to support market access of pancreatic cancer test in Germany

Immunovia announces agreement with Ehlers, Ehlers and Partner to develop and drive market access strategy of IMMray™ PanCan-d in Germany LUND, Sweden ― Immunovia, a life science company focused on developing blood-based diagnostic tests for cancer and autoimmune diseases, announced today that they enter into an advisory collaboration agreement with Ehlers, Ehlers and Partner which […]

March 8th, 2016
Immunovia launches Swedish website

LUND, Sweden ― Immunovia AB today introduces its website in Swedish as part of the efforts to grow its presence in the Scandinavian home markets. The company launched its global website one year ago and online reports show high total number of visitors from all around the world. However, since December last year, when the […]

February 29th, 2016
Immunovia starts collaboration with multinational life science company on new systemic lupus erythematosus (SLE) diagnostics test

Immunovia and a large multinational life science company have agreed to run two studies aimed at evaluating Immunovia’s IMMray™ SLE-d for diagnosis of SLE LUND, Sweden ― Immunovia AB announced today that the company has entered into an agreement with a large multinational life science company to run joint studies aimed at expanding the applications […]

February 29th, 2016
Immunovia inleder samarbete med multinationellt Life Science-företag om nytt diagnostiskt test inom Systemisk Lupus Erythematosus (SLE)

Tillsammans med ett stort multinationellt Life Science-företag kommer Immunovia att utföra två studier för att utvärdera Immunovias IMMray™ SLE-d för diagnos av SLE LUND, Sverige – Immunovia AB meddelar att de idag har ingått ett samarbete med ett stort multinationellt Life Science-företag. Tillsammans ska de genomföra studier som syftar till att utöka applikationsområdet för IMMray™ […]

February 24th, 2016
Immunovia releases today Year-end Report 2015

“In 2015 Immunovia took important steps toward commercialisation of the world’s first blood-based test for cancer diagnosis, IMMray™ PanCan –d. We were able to prove, with 96% accuracy, that our test can diagnose the early stages of pancreatic cancer. In the second half of the year we signed a comprehensive agreement with Knight Cancer Institute […]

February 24th, 2016
Immunovia publicerar idag Bokslutskommuniké 2015

“Under 2015 tog Immunovia viktiga steg för en kommersialisering av världens första blodbaserade test för cancerdiagnostik, IMMray™ PanCan –d. Vi kunde påvisa att vårt test med 96 procentig noggrannhet kan diagnostisera tidiga stadier av pankreascancer. Under andra halvåret tecknade vi ett omfattande avtal med Knight Cancer Institute på Oregon Health & Science University, USA vilka […]

February 23rd, 2016
Immunovia inbjuder till telefonkonferens den 24 februari 2016

Immunovia inbjuder till telefonkonferens i samband med rapportering av helårsresultatet för 2015. Telefonkonferensen äger rum kl. 16.00 den 24 februari och resultatet beräknas publiceras kl. 14.00 samma dag. Immunovia inbjuder till telefonkonferens i samband med rapportering av helårsresultatet för 2015. Telefonkonferensen som beräknas pågå i maximalt en timme kommer att hållas på svenska. Efter en […]

February 16th, 2016
Immunovia presenterar vid Vator Securities Unicorn Summit

Vator Securities Unicorn Summit är en kapitalmarknadsdag med några av de mest intressanta svenska Life Science-bolagen. Eventet anordnas den 9 mars 2016 på IVA i Stockholm, med start klockan 15:00. LUND, Sverige – Immunovia AB är ett av fem utvalda bolag som ska presentera under eftermiddagen. För presentationen, som börjar klockan 16:00 står Mats Grahn, […]

February 10th, 2016
Immunovia and Lund University start clinical validation studies of Systemic Lupus Erythematosus (SLE) biomarker signatures

Immunovia initiates a new program to focus on the development, validation and commercialization of antibody array based tests for differential diagnostics and for prediction/monitoring of flares for SLE also known as “lupus”. LUND, Sweden ― Immunovia AB announced today that the company is expanding the applications area of IMMray™, its proprietary antibody biomarker based technology […]

February 10th, 2016
Immunovia och Lunds universitet påbörjar valideringsstudier avseende test för diagnostisering av Lupus (SLE)

Immunovia påbörjar ett nytt program fokuserat på utveckling, validering och kommersialisering av blodbaserade antikroppsarraytester för differentialdiagnos och för prediktion/monitorering av skov vid SLE, även känd som “lupus”. LUND, Sverige – Immunovia AB meddelar idag att de expanderar applikationsområdet för IMMray™, deras egenutvecklade antikroppsbaserade teknologiplattform, till autoimmuna sjukdomar. “Uppskattningsvis lider cirka fem miljoner människor av SLE […]

February 9th, 2016
Immunovia announces collaboration with Mount Sinai Health System to validate early detection blood test for pancreatic cancer in a prospective clinical study

LUND, Sweden, and NEW YORK, USA ― Immunovia AB is pleased to announce that Mount Sinai Health System will be one of the first sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites […]

February 9th, 2016
Immunovia inleder samarbete med Mount Sinai Health System för validering av blodprovstest för tidig upptäckt av pankreascancer i en klinisk prospektiv studie

LUND, Sverige och New York, USA – Immunovia AB har nöjet att meddela att Mount Sinai Health System kommer att vara ett av de cancercenter som deltar i en klinisk prospektiv studie för tidig diagnos av pankreascancer. Studien ska validera Immunovias blodprovstest, IMMray™ PanCan-d, och kommer att genomföras på flera cancercenter både i USA och […]

January 19th, 2016
Immunovia and the University of Liverpool enter into collaboration to validate early detection blood test for pancreatic cancer in a prospective clinical study

LUND, Sweden, and Liverpool, UK ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that the first European site participating in its prospective clinical study for the early diagnosis of pancreatic cancer will be the National Institute for Health Research (NIHR) Pancreatic Biomedical […]

January 19th, 2016
Immunovia och University of Liverpool inleder samarbete för att validera blodbaserat test för tidig upptäckt av bukspottkörtelcancer i en prospektiv klinisk studie

LUND, Sverige, och Liverpool, Storbritannien – I linje med Immunovias strategi att leverera det första validerade testet för tidig diagnos av pankreascancer meddelar företaget att Pancreatic Biomedical Research Unit inom NIHR, det nationella institutet för hälsoforskning vid Royal Liverpool University Hospital, blir den första europeiska enheten som deltar i den prospektiva kliniska studien för tidig […]

December 18th, 2015
White Paper outlines predicted impact of new biomarker diagnostic technology on pancreatic cancer survival rates

LUND, Sweden ― In this White Paper, Immunovia summarizes the clinical evidence retrospective studies performed so far on pancreatic cancer with IMMray™ PanCan-d. The blood based biomarker signature is able to detect pancreatic cancer in all stages, especially in resectable stage I and II, and thus has the potential to improve 5-year patient survival rates […]

December 18th, 2015
Ett White Paper beskriver uppskattad effekt av ny biomarkördiagnostik på överlevnad vid pankreascancer

LUND, Sverige – I ett White Paper sammanfattar Immunovia kliniska bevis från de retrospektiva studier som hittills utförts på pankreascancer med IMMray™ PanCan-d. Testet med blodbaserade biomarkörsignaturer upptäcker pankreascancer i alla stadier, framförallt i de opererbara cancerstadierna I och II, och har därmed potential att förbättra patienternas 5-års överlevnad från 4-6 % till 50-60 %. […]

December 3rd, 2015
IMMray™ PanCan-d upptäcker 98 procent av alla fall av pankreascancer i en retrospektiv studie av 1 400 blodprov

Den största studien någonsin för diagnos av pankreascancer banar vägen för tidig intervention som kan öka överlevnaden avsevärt. LUND ― CREATE Health – strategiskt centrum för translationell cancerforskning i Lund i samarbete med Immunovia tillkännagav idag att de har slutfört en retrospektiv studie som visar att med 96 procents noggrannhet kan testet IMMray™ PanCan-d skilja […]

December 3rd, 2015
IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples

Largest ever study for diagnosing pancreatic cancer paves way for early intervention to significantly improve survival rates. LUND, Sweden ― CREATE Health Translational Cancer Center, Lund, Sweden in collaboration with Immunovia today announced that they have completed a retrospective study demonstrating that the IMMray™ PanCan-d test is able to differentiate with 96% accuracy patients with […]

December 2nd, 2015
Immunovias aktie steg 60 procent första handelsdagen på Nasdaq First North och omsatte 28,5 miljoner kronor

Aktier i Immunovia AB (IMMNOV) kunde igår för första gången handlas på Nasdaq Stockholm First North. Vid stängning hade aktiekursen stigit med 60 procent jämfört med introduktionspriset. Intresset från investerare var stort. Aktier för 28,5 miljoner kronor omsattes under dagen, vilket är rekord i förhållande till jämförbara noteringar på First North under 2015. Immunovia är […]

December 2nd, 2015
Immunovia’s stock increased 60 percent on first day of trading on Nasdaq First North with a turnover of SEK 28.5 million

Trading in Immunovia AB’s shares (IMMNOV) commenced yesterday on Nasdaq First North in Stockholm. At closing the share price had surged 60 percent compared to the introduction price. The interest among investors was high. The trading turnover was SEK 28.5 million during the day, thus setting a new record among comparable First North listings during […]

November 26th, 2015
Immunovia approved for trading on Nasdaq First North as of December 1st, 2015

Immunovia AB (publ) has been approved for trading of its shares on Nasdaq First North in Stockholm. The first trading day is December 1st, 2015. Immunovia is a Swedish research company that has developed a new method for using a blood test to diagnose pancreatic cancer. With Immunovia’s test, diagnosis can be made earlier which […]

November 26th, 2015
Immunovia godkänt för handel på Nasdaq First North från 1 december 2015

Immunovia AB (publ) har erhållit godkännande för upptagande till handel av bolagets aktier på Nasdaq First North. Första handelsdag är den 1 december 2015. Immunovia är ett svenskt forskningsbolag som har utvecklat en ny metod för att med hjälp av blodprov diagnostisera pankreascancer. Med Immunovias test kan diagnos ställas tidigare vilket ger väsentligt förbättrade möjligheter […]

November 19th, 2015
Immunovia’s share issue oversubscribed five times prior to listing on the Nasdaq First North in Stockholm

Immunovia’s share issue oversubscribed five times prior to listing on the Nasdaq First North in Stockholm The new share issue of Immunovia AB’s (publ) (“Immunovia” or the “Company”) prior to listing on Nasdaq First North was subscribed to SEK 305 million, representing a subscription rate of 500 percent. The issue provides the Company with SEK […]

November 19th, 2015
Immunovias nyemission övertecknad fem gånger inför notering på Nasdaq First North

Nyemissionen i Immunovia AB (publ) (”Immunovia” eller ”Bolaget”) inför Bolagets notering på Nasdaq First North blev tecknad till 305 miljoner kronor, vilket motsvarar en teckningsgrad om cirka 500 procent. Genom emissionen tillförs Bolaget därigenom 60 MSEK före emissionskostnader och får omkring 1 100 nya aktieägare. Beräknad första dag för handel med Bolagets aktie på Nasdaq […]

October 30th, 2015
Immunovia AB offentliggör prospekt avseende nyemission av aktier inför notering på Nasdaq First North

Detta pressmeddelande får inte offentliggöras, publiceras eller distribueras, direkt eller indirekt inom eller till USA, Australien, Hongkong, Kanada, Japan eller Singapore eller i någon annan jurisdiktion där distributionen av detta pressmeddelande skulle vara föremål för legala restriktioner. Immunovia AB (publ) (”Immunovia” eller ”Bolaget”) har upprättat ett prospekt avseende nyemission av aktier inför notering av Bolagets […]

October 5th, 2015
Immunovia och Knight Cancer Institute gör gemensam satsning för tidig upptäckt av pankreascancer (Swedish)

LUND, Sverige, och PORTLAND, Oregon – Immunovia AB inleder nu ett samarbete med Knight Cancer Institute på Oregon Health & Science University (OHSU). En viktig milstolpe i den kliniska valideringen och kommersialiseringen i USA av Immunovias första test för tidig diagnos av pankreascancer. Cancer i pankreas är en av de dödligaste cancerformerna, med en fem-års […]

October 5th, 2015
Immunovia, OHSU collaborating on early detection test for pancreatic cancer

LUND, Sweden, and PORTLAND, Oregon ― Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration […]

October 5th, 2015
Teknologiplattformen IMMrayTM presenteras idag i Sveriges Radio, Sydsvenskan, SVT1 Rapport

Christer Wingren, professor vid avdelningen för immunteknologi i Lund samt Chief Technology Officer på Immunovia AB, intervjuas idag på Sveriges Radio om tekniken som upptäcker en särskilt svårbehandlad form av cancer. Det är nämligen forskare vid CREATE Health Translational Cancer Center vid Lunds Universitet som tagit fram ett test som med ett enkelt blodprov visar […]

September 11th, 2015
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (publ)

Immunovia går nu in i en kommersiell fas där erfarenhet av marknadsintroduktioner av banbrytande teknologi i den medicinska branschen blir mycket viktigt för bolaget. För att stärka styrelsen med detta som bakgrund föreslår ägare med över 44% av aktiekapitalet nyval av 2 ledamöter. Styrelsen i Immunovia AB (publ), org nr 556730-4299, kallar härmed till extra […]

May 18th, 2015
KALLELSE TILL ÅRSSTÄMMA I IMMUNOVIA AB (in Swedish only)

KALLELSE TILL ÅRSSTÄMMA I IMMUNOVIA AB Styrelsen i Immunovia AB, org nr 556730-4299, kallar härmed till årsstämma. Datum:                 2015-06-01 Tid:                       16.00 Plats:                    Samlingslokal Tellus 301, Medicon Village, Scheelevägen 2, 223 63 Lund Anmälan/rätt att delta på stämman Aktieägare som vill delta i bolagsstämman skall vara införd i den av Euroclear Sweden AB förda aktieboken tisdagen […]

March 23rd, 2015
Immunovia har fått ett anslag på 40 miljoner kronor godkänt av EUs ramprogram för forskning och innovation, Horizon 2020

Immunovia har fått ett anslag på 40 miljoner kronor godkänt av EUs forsknings- och innovations ramprogram Horizon 2020, för att genomföra klinisk validering av det första blodbaserade testet för tidig detektion av bukspottkörtel cancer.   (Lund, Sverige, 23 mars, 2015) Immunovia AB annonserar idag att företaget har fått en ansökan på 4,2 miljoner euro, ca […]

March 23rd, 2015
Immunovia receives the approval of a € 4.2 million grant from EU Research and Innovation Programme Horizon 2020

Immunovia receives the approval of a € 4.2 million grant, from the EU research and innovation framework programme Horizon 2020 for the clinical validation of the first blood based test for early detection of pancreatic cancer   (Lund, Sweden, March, 23, 2015) Immunovia AB announced today that the company received the approval for a two-year […]

March 9th, 2015
A short overview of the connections between diabetes and pancreatic cancer

Up to 85% of pancreatic cancer patients also develop diabetes or hypoglycaemia and patients with new-onset diabetes run a 5-8 fold increased risk of being diagnosed with pancreatic cancer. The connection between diabetes and pancreatic cancer has been known and investigated since the late 19th century, but still no clear picture has emerged explaining the […]

December 17th, 2014
Immunovia will introduce its blood based test for early detection of pancreatic cancer firstly in the US

Immunovia, a company located in Lund, Sweden, will introduce a blood test for early detection of pancreatic cancer. The company created by investigators at Create Health Cancer Center in Lund, has developed an antibody array technology platform that is using the immune system as an early, specific and sensitive sensor for the disease. The test […]

November 1st, 2014
A new weapon to beat pancreatic cancer? Näringsliv, Sweden, nr 5

This article presents in general terms Immunovia´s blood based test for early diagnosis of pancreatic cancer. The article provides an overview of the antibody based microarray technology that can be applied to other autoimmune diseases and cancers. Click here to read more (pdf)

September 22nd, 2014
Framgångsrik kapitalanskaffning (article in Swedish)

Immunovia AB, ett molekylärdiagnostikbolag baserat på en banbrytande teknologi som möjliggör tidig diagnostik av komplexa sjukdomar såsom cancer, där det idag helt saknas kliniskt fungerande lösningar, tillkännager idag 20 maj 2014 slutförandet av en kapitalanskaffning i en övertecknad nyemission om 43 miljoner kronor. Immunovia AB är ett svenskt bolag som har utvecklat vad som kan […]

March 4th, 2013
Grading breast cancer tissues using molecular portraits.

Olsson, N., Carlsson, P., James, P., Hansson, K., Malmström, P., Fernö, M., Ryden, M., Wingren, C., and Borrebaeck, CAK.,  Mol. Cell. Proteomics. 2013, 12, 3612-3623.    

March 4th, 2011
Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases.

Carlsson, A., Wingren, C., Kristensson, M., Fernö, M., Olsson, H., Peterson, C., Borrebaeck, CAK.  Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 14252-7.

March 4th, 2008
Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.

Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P., Baldertorp, B., Fernö, M., Olsson, H., and Borrebaeck, CAK.  European Journal of Cancer. 2008, 44, 472-480.